Combined blockade of PI3K/AKT and EGFR/HER3 enhances antitumor activity in triple negative breast cancer

被引：0
|
作者：
Scaltriti, Maurizio [1 ]
Tao, Jessica [2 ]
Juric, Dejan [2 ]
Auricchio, Neil [2 ]
Castel, Pau [1 ]
Morse, Natasha [1 ]
Kim, Phillip [3 ]
Singh, Sharat [3 ]
Hazra, Saswati [3 ]
Hembrough, Todd [4 ]
Burrows, Jon [4 ]
Baselga, Jose [1 ]
机构：
[1] Mem Sloan Kettering Canc Ctr, New York, NY USA
[2] Massachusetts Gen Hosp, Ctr Canc, Boston, MA 02114 USA
[3] Prometheus Lab Therapeut & Diagnost, San Diego, CA USA
[4] OncoPlexDx, Rockville, MD USA
来源：
CANCER RESEARCH | 2013年 / 73卷 / 08期
关键词：
D O I：
10.1158/1538-7445.AM2013-4471
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4471
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Blockade of EGFR and HER3 enhances PI3K/Akt antitumor activity in triple negative breast cancer
    Scaltriti, Maurizio
    Tao, Jessica
    Castel, Pau
    Radosevic-Robin, Nina
    Elkabets, Moshe
    Auricchio, Neil
    Juric, Dejan
    Penault-Llorca, Frederique
    Baselga, Jose
    CANCER RESEARCH, 2014, 74 (19)
  • [2] Combined Blockade of PI3K/AKT and EGFR/HER3 Enhances Anti-Tumor Activity in Triple Negative Breast Cancer
    Tao, J.
    Ip, P.
    Auricchio, N.
    Juric, D.
    Yu, M.
    Shyamala, M.
    Kim, P.
    Singh, S.
    Hazra, S.
    Haber, D.
    Scaltriti, M.
    Baselga, J.
    CANCER RESEARCH, 2012, 72
  • [3] Antagonism of EGFR and HER3 Enhances the Response to Inhibitors of the PI3K-Akt Pathway in Triple-Negative Breast Cancer
    Tao, Jessica J.
    Castel, Pau
    Radosevic-Robin, Nina
    Elkabets, Moshe
    Auricchio, Neil
    Aceto, Nicola
    Weitsman, Gregory
    Barber, Paul
    Vojnovic, Borivoj
    Ellis, Haley
    Morse, Natasha
    Viola-Villegas, Nerissa Therese
    Bosch, Ana
    Juric, Dejan
    Hazra, Saswati
    Singh, Sharat
    Kim, Phillip
    Bergamaschi, Anna
    Maheswaran, Shyamala
    Ng, Tony
    Penault-Llorca, Frederique
    Lewis, Jason S.
    Carey, Lisa A.
    Perou, Charles M.
    Baselga, Jose
    Scaltriti, Maurizio
    SCIENCE SIGNALING, 2014, 7 (318)
  • [4] Targeting of HER3 potentiates the antitumor activity of paclitaxel against triple negative breast cancer
    Lyu, Hui
    Ruan, Sanbao
    Tan, Congcong
    Thor, Ann
    Liu, Bolin
    CANCER RESEARCH, 2024, 84 (09)
  • [5] HER3 LIMITS THE ANTITUMOR ACTIVITY OF PI3K-AKT INHIBITORS IN TNBC
    不详
    CANCER DISCOVERY, 2014, 4 (06) : 630 - 630
  • [6] Targeting PI3K/AKT pathway in triple-negative breast cancer
    Delaloge, Suzette
    DeForceville, Louise
    LANCET ONCOLOGY, 2017, 18 (10): : 1293 - 1294
  • [7] PI3Kγδ inhibitor combined radiation enhances the antitumor immune effect of PD-1 blockade in syngenic triple negative breast cancer models.
    Kim, In Ah
    Han, Min Guk
    Jang, Bum Sup
    Kang, Mi Hyun
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [8] ANTITUMOR ACTIVITY OF PI3K ANTAGONIST AEZS126*IN MODELS OF TRIPLE NEGATIVE BREAST CANCER
    Engel, J. B.
    Schmidt, H.
    Haeussler, S.
    Diessner, J.
    Hahne, J.
    Meyer, S.
    Wischhusen, J.
    Dietl, J.
    Hoenig, A.
    ANTICANCER RESEARCH, 2011, 31 (05) : 1967 - 1968
  • [9] PI3K/AKT/mTOR inhibitors for the management of triple-negative breast cancer
    Kadri Altundag
    Medical Oncology, 41 (11)
  • [10] Neprilysin: A potential regulator of PI3K/AKT signaling in triple negative breast cancer cells
    Conway, Rebecca E.
    Iglesias, Katherine
    Hired, Zuhaila
    Rutledge, Grace
    Kirmani, Khadija
    CANCER RESEARCH, 2019, 79 (13)
12345